脑MRI虚拟对比增强能否替代钆剂?一项可行性研究
本研究开发了一种贝叶斯深度学习架构,利用注射钆基对比剂前的10通道多参数脑MRI预测虚拟对比增强,并在116例胶质瘤患者和健康受试者中与真实增强T1加权成像对照。定量敏感度91.8%、特异度91.2%,全脑平均AUC为0.969±0.019;两名放射科医师通过Turing测试分别以80%和90%的准确率区分真实与虚拟增强图像。
要点
- 虚拟增强全脑平均AUC为0.969±0.019,敏感度91.8%、特异度91.2%。
- T2加权成像是对虚拟增强预测影响最大的序列,其次为扩散加权成像。
- 虚拟增强图像存在更模糊、环状增强结节感减弱、遗漏小血管等视觉偏差。
核心结论
- 虚拟钆增强模型在定量和定性评估中表现很好,但需在更大规模、不同神经系统疾病患者中系统研究,评估其能否在临床实践中减少钆基对比剂暴露。
研究设计与样本
- 可行性研究,采用贝叶斯深度学习架构,基于注射钆基对比剂前的10通道多参数脑MRI预测虚拟对比增强。
关键影像表现/征象
- 虚拟增强图与真实增强T1加权成像相比,表现为环状增强更模糊、结节感减弱,非增强胶质瘤出现少量低对比度假阳性增强,并有遗漏小血管的倾向。
诊断标准与关键数值
- 以真实增强T1加权成像为参考标准,虚拟增强定量敏感度91.8%、特异度91.2%;全脑平均AUC为0.969±0.019,峰值信噪比22.967±1.162 dB,结构相似性指数0.872±0.031。
临床应用与阅片要点
- 两名受过训练的放射科医师通过Turing测试区分真实与虚拟增强图像,准确率分别为80%和90%;两名评估者采用4点Likert量表定性评价,91.5%的增强胶质瘤和92.3%的非增强胶质瘤获得良好至优秀(3-4分)结果。
局限性
- 原文指出未来需在更大规模、不同神经系统疾病患者集合中开展系统研究,以评估虚拟对比增强能否在临床实践中减少钆基对比剂暴露。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Gadolinium-based contrast agents (GBCAs) have become an integral part in daily clinical decision making in the last 3 decades. However, there is a broad consensus that GBCAs should be exclusively used if no contrast-free magnetic resonance imaging (MRI) technique is available to reduce the amount of applied GBCAs in patients. In the current study, we investigate the possibility of predicting contrast enhancement from noncontrast multiparametric brain MRI scans using a deep-learning (DL) architecture.
MATERIALS AND METHODS: A Bayesian DL architecture for the prediction of virtual contrast enhancement was developed using 10-channel multiparametric MRI data acquired before GBCA application. The model was quantitatively and qualitatively evaluated on 116 data sets from glioma patients and healthy subjects by comparing the virtual contrast enhancement maps to the ground truth contrast-enhanced T1-weighted imaging. Subjects were split in 3 different groups: enhancing tumors (n = 47), nonenhancing tumors (n = 39), and patients without pathologic changes (n = 30). The tumor regions were segmented for a detailed analysis of subregions. The influence of the different MRI sequences was determined.
RESULTS: Quantitative results of the virtual contrast enhancement yielded a sensitivity of 91.8% and a specificity of 91.2%. T2-weighted imaging, followed by diffusion-weighted imaging, was the most influential sequence for the prediction of virtual contrast enhancement. Analysis of the whole brain showed a mean area under the curve of 0.969 ± 0.019, a peak signal-to-noise ratio of 22.967 ± 1.162 dB, and a structural similarity index of 0.872 ± 0.031. Enhancing and nonenhancing tumor subregions performed worse (except for the peak signal-to-noise ratio of the nonenhancing tumors). The qualitative evaluation by 2 raters using a 4-point Likert scale showed good to excellent (3-4) results for 91.5% of the enhancing and 92.3% of the nonenhancing gliomas. However, despite the good scores and ratings, there were visual deviations between the virtual contrast maps and the ground truth, including a more blurry, less nodular-like ring enhancement, few low-contrast false-positive enhancements of nonenhancing gliomas, and a tendency to omit smaller vessels. These "features" were also exploited by 2 trained radiologists when performing a Turing test, allowing them to discriminate between real and virtual contrast-enhanced images in 80% and 90% of the cases, respectively.
CONCLUSIONS: The introduced model for virtual gadolinium enhancement demonstrates a very good quantitative and qualitative performance. Future systematic studies in larger patient collectives with varying neurological disorders need to evaluate if the introduced virtual contrast enhancement might reduce GBCA exposure in clinical practice.
引用
- Kleesiek J, Morshuis JN, Isensee F, et al. Can Virtual Contrast Enhancement in Brain MRI Replace Gadolinium?: A Feasibility Study. Invest Radiol. 2019. PMID: 31261293. doi:10.1097/RLI.0000000000000583
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。